Patent ID: 9683986
Date: 2017-06-20
CPC Classifications: G01N

Claim:
1. An in vitro method for selecting compounds capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer comprising the following steps: a) providing at least one candidate compound; b) providing transformed cells expressing stably MyD88 under the control of an inducible promoter and expressing a reporter gene under the control of a promoter from the MAPK pathway selected from the group consisting of an SRE promoter, an ELK promoter and a MyC promoter; c) inducing overexpression of MYD88 in the transformed cells in the presence of the at least one candidate compound; d) measuring the expression of the reporter gene and selecting the at least a one candidate compound when the at least one candidate compound inhibits the expression of the reporter gene; e) providing immortalized fibroblasts transformed by transfection with the MyD88 and Myc oncogenes; and f) in a focus formation assay, monitoring focus formation in the presence of the at least one candidate compound that inhibits expression of the reporter gene selected in step d) and in the presence of at least one DNA damage inducing chemotherapy agent, and selecting the at least one compound when the at least one compound potentiates the inhibitory effect of the DNA damage inducing chemotherapy agent on the focus formation; wherein the DNA damage inducing chemotherapy agent is selected from the group consisting of oxaliplatin, cisplatin, carboplatin, doxorubicin, etoposide, bleomycin and mixtures thereof.